Back to News
Dec 19, 2025 12:00 PM

GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) on Thursday entered into a strategic research, collaboration, and license agreement with GSK Plc (NYSE:GSK).

The collaboration aims to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications.

Under the terms of the agreement, CAMP4 will receive a $17.5 million cash upfront payment.

Also Read: FDA Approves GSK’s Drug, Targets Severe Asthma With Two Doses Per Year

Additionally, CAMP4 has the potential to receive additional payments for certain development and commercial milestones, in addition to tiered royalties on future product sales.

CAMP4 will utilize its proprietary RAP Platform to identify regRNAs controlling the expression of multiple ...